Drug intelligence / Profile preview

RA02AB

Development stage: Preclinical
Lead developer: Remab Therapeutics
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

RA02AB is a polymeric glycoconjugate being developed by Remab Therapeutics for the selective intracorporeal removal of anti-A and anti-B blood group antibodies. The drug is designed to prevent ABO blood transfusion reactions and hyperacute rejection in vascularized organ transplantation by neutralizing specific blood group antibodies that cause complement fixation and intravascular hemolysis. RA02AB utilizes carbohydrate derivatives of blood group A and B antigens (RA02A and RA02B) as part of its platform technology for selective antibody removal. It is currently in preclinical development.

Other names: RA02ARA-02ARA 02ARA02BRA-02BRA 02B

Targets

Anti-B (Anti-B antibody)

Beyond the preview

Go deeper on RA02AB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA02AB.

Explore the full profile